LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

Search

BioCryst Pharmaceuticals Inc

Open

Branche Gesundheitswesen

6 -3.85

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6

Max

6.07

Schlüsselkennzahlen

By Trading Economics

Einkommen

39M

-36M

Verkäufe

6.7M

93M

EPS

-0.28

Gewinnspanne

-41.674

Angestellte

536

EBITDA

-20M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+155.5 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

1. Aug. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

41M

990M

Vorheriger Eröffnungskurs

9.85

Vorheriger Schlusskurs

6

Nachrichtenstimmung

By Acuity

50%

50%

124 / 370 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

BioCryst Pharmaceuticals Inc Chart

Ähnliche Nachrichten

18. Juni 2024, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia in Deal to Buy Software Startup Shoreline.io, Bloomberg Reports

18. Juni 2024, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Circle K, Global Partners Sell Dozens of U.S. Stores -- OPIS

18. Juni 2024, 21:36 UTC

Market Talk

Fitch Affirms Canadian Bank Ratings, Citing Pending BOC Rate Cuts -- Market Talk

18. Juni 2024, 20:59 UTC

Top News

Exxon Lawsuit Against Activist Shareholders Thrown Out -- WSJ

18. Juni 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18. Juni 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Juni 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Juni 2024, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

Silk Road Medicine Rockets On Boston Scientific's $1.16 Billion Takeover -- IBD

18. Juni 2024, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juni 2024, 19:59 UTC

Market Talk

Canada Finance Officials Aware of 'Rebalancing' in Labor Market -- Market Talk

18. Juni 2024, 19:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Juni 2024, 19:43 UTC

Market Talk

Gold Stays Elevated as Central Banks Continue To Buy -- Market Talk

18. Juni 2024, 19:17 UTC

Ergebnisse

Investors Shrugged Off Zyn's Latest Trouble. Nicotine Pouches Still Aren't in the Clear. -- Barrons.com

18. Juni 2024, 19:07 UTC

Market Talk

Oil Futures Advance as Traders Bet on Seasonal Demand -- Market Talk

18. Juni 2024, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

18. Juni 2024, 18:00 UTC

Top News

Amazon Fined by California for Failure to Disclose Worker Quotas -- WSJ

18. Juni 2024, 17:17 UTC

Market Talk

Brazil's Central Bank Expected To Pause Easing -- Market Talk

18. Juni 2024, 17:12 UTC

Market Talk

U.S. Home Prices Rise At Slowest Rate in Nearly 18 Months -- Market Talk

18. Juni 2024, 17:00 UTC

Ergebnisse

Kroger Earnings Due As Grocery Archrivals Walmart, Costco Snatch All-Time Highs -- IBD

18. Juni 2024, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

18. Juni 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Juni 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Juni 2024, 15:59 UTC

Akquisitionen, Fusionen, Übernahmen

Citi Stock Gains as Bank Showcases an Overlooked Business -- Barrons.com

18. Juni 2024, 15:37 UTC

Market Talk

Oil Gains on Expectations of Tighter Market Over Summer -- Market Talk

18. Juni 2024, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Juni 2024, 15:35 UTC

Market Talk

German Economic Sentiment Has Plateaued, But Recovery Still on Track -- Market Talk

18. Juni 2024, 15:32 UTC

Market Talk

Some Steam Expected to Come Out of Gold Price as Rates Fall -- Market Talk

18. Juni 2024, 15:28 UTC

Market Talk

German Economic Sentiment Shrugs off Political Uncertainty -- Market Talk

18. Juni 2024, 15:00 UTC

Market Talk

Kering Will Continue to Face Challenges -- Market Talk

18. Juni 2024, 14:51 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Proxy ISS Supports BBVA's Bid for Sabadell -- Market Talk

Peer-Vergleich

Kursveränderung

BioCryst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

155.5% Vorteil

12-Monats-Prognose

Durchschnitt 15.33 USD  155.5%

Hoch 30 USD

Tief 6 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioCryst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

6.1 / 7.65Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

124 / 370 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.